The post-NSAID era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis

Current Rheumatology Reports

Volumn 10, Issue 1, 2008, Pages 49-56

  Scanzello, Carla R ^a   Moskowitz, Neal K ^b   Gibofsky, Allan ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; CELECOXIB; CHONDROITIN SULFATE; CORTICOSTEROID DERIVATIVE; DIACETYLRHEIN; DICLOFENAC; DIMETHYL SULFONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; EUFLEXXA; FENTANYL; GINGER EXTRACT; GLUCOSAMINE SULFATE; HERBACEOUS AGENT; HYALURONIC ACID; HYALURONIC ACID DERIVATIVE; LIDOCAINE; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRACEUTICAL; OPIATE; OXYCODONE; PARACETAMOL; PIASCLEDINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; S ADENOSYLMETHIONINE; TRAMADOL; UNCLASSIFIED DRUG; ANALGESIC AGENT;

AEROBIC EXERCISE; ANTIINFLAMMATORY ACTIVITY; BONE RADIOGRAPHY; BRACE; BURNING SENSATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DAILY LIFE ACTIVITY; DIZZINESS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEALTH PROGRAM; HIP OSTEOARTHRITIS; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; LIVER TOXICITY; MONOTHERAPY; MUSCLE STRENGTH; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; OCCUPATIONAL THERAPY; OSTEOARTHRITIS; PAIN; PATIENT EDUCATION; PHOTOSENSITIVITY; PHYSIOTHERAPY; RANGE OF MOTION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEIZURE THRESHOLD; SELF CARE; SHOE; SIDE EFFECT; SKIN IRRITATION; SOCIAL SUPPORT; SOMNOLENCE; TELECONSULTATION; TRANSDERMAL PATCH; VAGINA CANDIDIASIS; VAGINITIS; VOMITING; WEIGHT REDUCTION; DIET SUPPLEMENTATION; DRUG EFFECT; INNERVATION; JOINT; PATHOPHYSIOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; HUMANS; INFLAMMATION; JOINTS; OSTEOARTHRITIS; PAIN;

EID: 44949221245     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0009-6     Document Type: Review

References (60)

1. Lin EH, Tang L, Katen W, et al.: Arthritis pain and disability: response to collaborative depression care. Gen Hosp Psychiatry 2006, 28:482-486.
2. Bjordal JM, Ljunggren AE, Klovning A, Slordal L: Non-steroidal anti-inflammatory drugs, including cyclooxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomized placebo controlled trials. BMJ 2004, 329:1317.
3. Mitchell JA, Warner TD: COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006, 5:75-86.
4. Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4-15.
5. Patrono C: The PGH-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol 2006, 47(Suppl 1):S1-S6.
6. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
7. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954-959.
8. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
9. Singh G, Fort JG, Goldstein JL, et al.: Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006, 119:255-266.
10. Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885-895.
11. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
12. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
13. Solomon DH, Avorn J, Stürmer T, et al.: Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006, 54:1378-1389.
14. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al.: NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006, 27:1657-1663.
15. Singh G, Mithal A, Triadafilopoulos G: Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis 2005, 64(Suppl III):85.
16. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366.
17. Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-481.
18. Solomon DH, Schneeweiss S, Levin R, Avorn J: Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004, 44:140-145.
19. Solomon DH, Schneeweiss S, Glynn RJ, et al.: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068-2073.
20. Catella-Lawson F, Reilly MP, Kapoor SC, et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
21. Gaziano JM, Gibson CM: Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Am J Cardiol 2006, 97:23-29.
22. Krum H, Aw TJ, Liew D, Haas S: Blood pressure effects of COX-2 inhibitors. J Cardiovasc Pharmacol 2006, 47(Suppl 1):S43-S48.
23. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905-1915.
24. Bradley JD, Brandt KD, Katz BP, et al.: Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87-91.
25. Pincus T, Koch GG, Sokka T, et al.: A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587-1598.
26. Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis; a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003, 163:169-178.
27. Pincus T, Koch G, Lei J, et al.: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES); two randomized, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931-939.
28. Towheed TE, Maxwell L, Judd MG, et al.: Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006, 1:CD004257.
29. Curhan GC, Knight EL, Rosner B, et al.: Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004, 164:1519-1524.
30. Forman JP, Rimm EB, Curhan GC: Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007, 167:394-399.
31. Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578-1587.
32. Shipton AE: Tramadol--present and future. Anaesth Intensive Care 2000, 28:363-374.
33. Cepeda MS, Camargo F, Zea C, Valencia L: Tramadol for osteoarthritis: a systematic review and meta-analysis. J Rheumatol 2007, 34:543-555.
34. Markenson JA, Croft J, Zhang PG, Richards P: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005, 21:524-535.
35. Langford R, McKenna F, Ratcliffe S, et al.: Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1829-1837.
36. Golub LM, McNamara TF, D'Angelo G, et al.: A non-antibacterial chemically modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987, 66:1310-1314.
37. Cole AA, Chubinskaya S, Luchene LJ, et al.: Doxycycline disrupts chondrocyte differentiation and inhibits cartilage matrix degradation. Arthritis Rheum 1994, 37:1727-1734.
38. Yu LP Jr, Smith GN Jr, Brandt KD, et al.: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992, 35:1150-1159.
39. Brandt KD, Mazzuca SA, Katz BP, et al.: Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005, 52:2015-2025.
40. Little CB, Meeker CT, Golub SB, et al.: Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest 2007, 117:1627-1636.
41. Goldring SR, Goldring MB: The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004, 427(Suppl):S27-S36.
42. Pelletier JP, Yaron M, Haraoi B, et al.: Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. Arthritis Rheum 2000, 43:2339-2348.
43. Fidelix T, Soares B, Trevisani V: Diacerein for osteoarthritis. Cochrane Database Syst Rev 2005, 1:CD005117.
44. Bellamy N, Campbell J, Robinson B, et al.: Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, 2:CD005328.
45. Papachristou G, Anagnostou S, Katsorhis T: The effect of intraarticular hydrocortisone injection on the articular cartilage of rabbits. Acta Orthop Scan Suppl 1997, 275:132-134.
46. Bellamy N, Campbell J, Robinson B, et al.: Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, 2:CD005321.
47. Wang CT, Lin YT, Chiang BL, et al.: High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006, 14:1237-1247.
48. Chevalier X, Giraudeau B, Conrozier T, et al.: Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005, 32:1317-1323.
49. Deal CL, Schnitzer TJ, Lipstein E, et al.: Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991, 13:383-395.
50. Reinharth D: Capsaicin cream unpopular with patients. Arch Intern Med 2005, 165:702.
51. Lin J, Zhang W, Jones A, Doherty M: Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. BMJ 2004, 329:324.
52. Gammaitoni AR, Galer BS, Onawola R, et al.: Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004, 20(Suppl 2):S13-S19.
53. Burch F, Codding C, Patel N, et al.: Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004, 12:253-255.
54. Ernst E: Complementary or alternative therapies for osteoarthritis. Nat Clin Pract Rheumatol 2006, 2:74-80.
55. Theodosakis J, Adderly B, Fox B: The Arthritis Cure. New York: St. Martin's Press; 1997.
56. Clegg DO, Reda DJ, Harris CL, et al.: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Eng J Med 2006, 354:795-808.
57. Herrero-Beaumont G, Ivorra JAR, del Carmen Trabado M, et al.: Glucosamine sulfate in the treatment of knee osteoarthritis symptoms. Arthritis Rheum 2007, 56:555-567.
58. McAlindon TE, LaValley MP, Glin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000, 283:1469-1475.
59. Towheed TE, Maxwell L, Anastassiades TP, et al.: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, 2:CD002946.
60. Biggee BA, Blinn CM, Nuite M, et al.:Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis 2007, 66:260-262.